CheckMate914

CheckMate 914 Archives

CheckMate 914: Adjuvant nivolumab–ipilimumab not supported for high-risk RCC

옵디보, '신세포암'에서 희비 교차 < 암/혈액/희귀/소아청소년 < 암/혈액/희귀/소아청소년 < 학술 < 기사본문 - 메디칼업저버

Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma - The ASCO Post

Advances in Adjuvant Therapy for Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Pembrolizumab Shows Promise

Toni Choueiri, MD on X: Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the @TheLancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could

Et de 3 ! CheckMate 914 : encore un essai négatif en adjuvant pour le rein

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Singer

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Followin